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Summary Treatment with tamoxifen is associated with reduced incidence of myocardial infarction. As plasma homocysteine is an
independent risk factor for cardiovascular disease, we studied the effects of tamoxifen on plasma homocysteine in 66 healthy women
participating in the Italian prevention trial of breast cancer who were randomized in a double-blind manner to tamoxifen 20 mg day-' or
placebo for 5 years. They were aged between 35 and 70 years, had undergone previous hysterectomy for non-malignant conditions and had
no cont(aindications to the use of tamoxifen. Plasma levels of total homocysteine (tHcy) were measured at randomization and after 2 and 6
months. The mean ± s.d. plasma levels of tHcy were 7.59 + 1.71 lmol 1-', 7.25 ± 1.61 and 7.09 + 1.33 in the tamoxifen group and 8.07 ± 2.06,
7.93 ± 1.77 and 8.12 + 2.04 in the placebo group at 0, 2 and 6 months (P= 0.008 for the between-group difference over time). The higher the
baseline tHcy level, the greater was the lowering effect of tamoxifen. No statistically significant effect of age, body mass index or smoking
habit on baseline tHcy levels and its variation over time was found. In conclusion, tamoxifen (20 mg day-' for 6 months) decreased plasma
tHcy levels in healthy women. This effect may contribute to its protective effect on myocardial infarction.
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Tamoxifen, a non-steroidal oestrogen receptor modulator, is the
standard endocrine treatment for breast cancer, both in the pallia-
tive and adjuvant setting (Jaiyesimi et al, 1995). As tamoxifen
administration has been associated with a substantial reduction in
contralateral breast cancer in a meta-analysis of adjuvant studies
(early Breast Cancer Trialists' Collaborative Group, 1992), its
breast cancer preventive efficacy in at-risk women is currently
being assessed in large intervention trials (Powles, 1992; Smigel,
1992; Veronesi, 1995).
In light of the partial agonistic activity, which reflects the
complex regulation of oestrogen signalling in the body (Pennisi,
1996), tamoxifen treatment has also been associated with a reduc-
tion in coronary heart disease (Rutqvist et al, 1993; McDonald
et al, 1995), prevention of bone density loss (Love et al, 1992),
sporadic excess of venous thromboembolism (Fisher et al, 1989;
McDonald et al, 1995) and endometrial cancer (Rutqvist et al,
1987; Fisher et al, 1994) in adjuvant clinical trials.
Although part of the protective cardiovascular effect of tamox-
ifen may be associated to the modulation of cholesterol, lipopro-
teins and fibrinogen levels (Love et al, 1994), a recent uncontrolled
study showed that tamoxifen, given at a dose of 30 mg day-',
lowered total plasma homocysteine (tHcy) levels in patients with
advanced breast cancer (Anker et al, 1995). Homocysteine is a
sulphydryl amino acid derived from the metabolic conversion of
methionine, which proved to be an independent risk factor for
Received 9 September 1997
Revised 1 December 1997
Accepted 3 December 1997
Correspondence to: M Cattaneo, Haemophilia and Thrombosis Centre,
Via della Pace, 9, 20122 Milan, Italy
premature occlusive disease of the coronary, cerebral and periph-
eral arteries in case-control and prospective studies (Boushey et al,
1995; McCully, 1996; Graham et al, 1997). The observed lowering
effect of tamoxifen on tHcy could therefore contribute further to
explain the reduction in cardiovascular morbidity observed in some
trials of adjuvant therapy (Rutqvist et al, 1993; McDonald et al,
1995). Because ofthe interest in assessing the effect oftamoxifen at
the conventional dose of 20 mg day-' in the context of primary
prevention, we measured plasma tHcy in a consecutive cohort of
66 healthy women enrolled in a double-blind, placebo-controlled
prevention trial.
MATERIALS AND METHODS
We studied a consecutive cohort of 66 women participating in the
Italian prevention trial of tamoxifen who were attending the out-
patient clinic of the Italian League against Cancer, Milan. In this
trial, women are randomized in a double-blind manner to tamox-
ifen, 20 mg day-' orally or placebo for 5 years. The primary end
point is breast cancer incidence. A detailed description ofthe study
has been published elsewhere (Veronesi, 1995). Eligible women
were aged between 35 and 70 years, had previous hysterectomy
for non-malignant conditions and had no contraindications to the
use of tamoxifen. The study received Institutional Review Board
approval and all subjects granted a written informed consent.
Plasma tHcy levels were measured at 0, 2 and 6 months from
randomization in 66 consecutive subjects granting informed
consent for this ancillary study. Blinding was disclosed after the
completion of the analysis and approval by the Data Safety and
Monitoring Committee ofthe trial.
Fasting blood samples were taken in 12.9 mmol 1-' trisodium
citrate (nine parts of blood in one part of anticoagulant) between
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08.00 h and 10.00 h, immediately placed on ice and centrifuged at
1600g at 4°C for 15 min. The supernatant plasma was stored at
-80°C until assayed in a single session. Plasma tHcy (free and
protein bound) concentration was measured by high-performance
liquid chromatography (Waters Millipore 6000A pump, Millipore)
and fluorescence detection (Waters 474) using the method of
Ubbink et al (1991) with slight modifications (Zighetti et al, 1997).
Data were analysed using the SAS Procedure MIXED (SAS
Institute, Cary, NC, USA) for repeated measure analysis of vari-
ance (Hand and Taylor, 1986); the response variable was the
within-subject change in tHcy level with respect to the baseline
level. For such data, when the same variable is recorded at
repeated time points for the same subject, it is inappropriate to use
separate t-tests at each time point as these tests are not independent
of each other. A repeated-measure analysis is the most efficient
way to take into account the within- and between-subject variation
over time and hence provides the most appropriate test of the
hypothesis under study (the comparison of the within-subject
change in tHcy levels between the treatment groups). All data are
reported as means and standard deviation (SD).
RESULTS
The main subject characteristics in the tamoxifen and placebo
groups are reported in Table 1. At the baseline, all variables were
evenly distributed between groups, including plasma tHcy levels,
blood pressure levels, serum creatinine and percentage of subjects
with glucose intolerance (two vs none in the tamoxifen and
placebo group respectively) or first-degree family history of
cardiovascular disease (one vs none).
Changes in tHcy levels over time in the two treatment arms are
reported in Table 2. One subject in the control group was excluded
from the analysis because she had very high levels of tHcy at all
three time points (25.4, 32.2, and 18.5 gmol 1-' at 0, 2 and 6
months).
Normality of the response variable at each time and treatment
group was checked and the result was valid. The repeated measure
model showed a significant interaction between baseline tHcy
level, time and treatment group (P = 0.008). Specifically, the
higher the baseline the greater was the decrease in tHcy level, with
a significant difference between treated and control subjects at
6 months (treated subjects with baseline values higher than
9 gmol 1-' showed a reduction of2-3 imol 1-').
No statistically significant effect of age, body mass index or
smoking habit on baseline tHcy levels and its variation over time
was found (not shown).
DISCUSSION
In this study, we observed a significant decline of plasma tHcy
levels in women who had previous hysterectomy for non-
malignant conditions and were treated with tamoxifen at the dose
of 20 mg day-' for 6 months. As hyperhomocysteinaemia is an
independent graded risk factor for atherosclerotic vascular disease
(Boushey et al, 1995; McCully, 1996; Graham et al, 1997; Nyg'ard
et al, 1997), the reduction in tHcy concentration may partly
explain the preventive effect of tamoxifen on cardiovascular
morbidity observed in trials of adjuvant therapy (Rutqvuist et al,
1993; McDonald et al, 1995). It has been calculated that a decrease
of 2 ,tmol 1-' in plasma tHcy concentration ofwomen living in the
Table 1 Main subject characteristics at baseline
Tamoxifen Placebo
(n = 31) (n = 35)
Age 51.4+4.5 52.3+4.6
Body mass index 24.7 + 4.5 24.0 ± 3.0
Smoking habit
Current/former/never 7/5/19 8/9/18
Years from hysterectomy 9.6 ± 5.5 10.7+ 6.7
Current HRT 1 3
Total cholesterol
mg dl-1 223 33 239 34
mmol 1-' 5.77+0.85 6.18+0.18
Values are means ± s.d. HRT, hormone replacement therapy.
Table 2 Time course of plasma tHcy levels
Time Tamoxifen Placebo
(months) (n = 31) (n = 34)
tHcy (,umol I-')
0 7.59 ± 1.71 8.07 + 2.06
(6.96 and 8.22) (7.35 and 8.79)
2 7.25+ 1.61 7.93± 1.77
(6.66 and 7.84) (7.31 and 8.55)
6 7.09± 1.33 8.12±2.04
(6.60 and 7.58) (7.41 and 8.83)
Change in tHcy from baseline (,umol 1-1)
2 -0.35± 1.02 -0.13± 1.05
(-0.72 and 0.02) (-0.50 and 0.24)
6 -0.50± 1.16 0.06±0.93
(-0.93 and -0.07) (-0.26 and 0.38)
Values are means ± s.d. and (95% confidence interval). P= 0.008 for the
interaction between baseline tHcy level, time and treatment group in the
repeated measure model.
US would prevent between 6000 and 11 500 coronary deaths
annually (Boushey et al, 1995). Although in our study the mean
decrease in plasma tHcy in the tamoxifen group was approxi-
mately 0.5 ,umol 1-', it was as high as 2-3 ,umol 1-' in subjects with
baseline concentrations higher than 9 ,umol 1-'.
Hyperhomocysteinaemia is a risk factor not only for
atherothrombotic diseases but also for venous thrombosis (Falc6n
et al, 1994; den Heijer et al, 1996). Thus, the sporadic risk of
venous thromboembolism observed in breast cancer patients
treated with tamoxifen (Fisher et al, 1989; McDonald et al, 1995)
could be ascribed to the drug inhibitory effect on plasma
antithrombin III (Mannucci et al, 1996) or to its partial agonistic
effects on other oestrogen-regulated target systems, possibly
outweighing the protective effect due to the decrease in tHcy levels.
A previous uncontrolled study of 31 patients, mostly with
metastatic breast cancer (Anker et al, 1995), showed a greater mean
inhibitory effect oftamoxifen compared with our study. This differ-
ence may be due not only to the higher dose used (30 mg day-') but
also to the abnormal baseline tHcy levels observed in most breast
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cancer patients (mean 12.4gmol 1-') in comparison with normal
women (8-9 ,tmol 1-') (Andersson et al, 1992; Nyg'ard et al, 1995).
As the high tHcy levels found in breast cancer women might also
reflect the activity oftumour cells, the possibility that the inhibitory
effect induced by tamoxifen on tHcy was secondary to its anti-
tumoral activity cannot be convincingly ruled out. In contrast, our
controlled study in healthy women shows that the tHcy decline is a
direct biological effect oftamoxifen that is not mediated by its anti-
tumoral activity. Indeed, the observation of a similar effect with
oestrogen replacement therapy (van der Mooren et al, 1994)
suggests that the reduction oftHcy is related to the partial agonistic
effect oftamoxifen on oestrogen-regulated targets.
As the risk of endometrial cancer associated with tamoxifen
appears to be dose related (Rutqvist et al, 1987; van Leeuwen et al,
1994), with an excess being observed mostly at 40 mg day-'
(Rutqvist et al, 1987), the maintenance of a significant modulation
oftHcy at low dose supports the contention ofa better risk-benefit
ratio, a finding with potentially important implications for the
outcome ofthe ongoing prevention trials.
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